Zai Lab Limited (HKG: 9688)

Market Cap	23.12B
Revenue (ttm)	2.76B
Net Income (ttm)	-2.10B
Shares Out	n/a
EPS (ttm)	-21.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	181,187
Average Volume	1,704,303
Open	20.75
Previous Close	20.50
Day's Range	20.75 - 21.10
52-Week Range	10.56 - 25.80
Beta	1.04
RSI	53.96
Earnings Date	Feb 27, 2025

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia grav...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 2,175
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9688

Financial Performance

In 2023, Zai Lab's revenue was $266.72 million, an increase of 24.03% compared to the previous year's $215.04 million. Losses were -$334.62 million, -24.51% less than in 2022.

Financial numbers in USD